Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Payables: 2009-2024

Historic Payables for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $20.4 million.

  • Cytokinetics' Payables rose 90.69% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 30.79%. This contributed to the annual value of $20.4 million for FY2024, which is 5.29% down from last year.
  • Cytokinetics' Payables amounted to $20.4 million in FY2024, which was down 5.29% from $21.5 million recorded in FY2023.
  • Cytokinetics' 5-year Payables high stood at $25.6 million for FY2022, and its period low was $8.1 million during FY2020.
  • Over the past 3 years, Cytokinetics' median Payables value was $21.5 million (recorded in 2023), while the average stood at $22.5 million.
  • Per our database at Business Quant, Cytokinetics' Payables spiked by 161.95% in 2021 and then fell by 16.02% in 2023.
  • Yearly analysis of 5 years shows Cytokinetics' Payables stood at $8.1 million in 2020, then surged by 161.95% to $21.1 million in 2021, then climbed by 21.45% to $25.6 million in 2022, then dropped by 16.02% to $21.5 million in 2023, then fell by 5.29% to $20.4 million in 2024.